Leica Biosystems partners with Molecular Instruments to enhance RNA-ISH research
In a move set to transform cancer diagnostics and research, Leica Biosystems, a global leader in diagnostic workflow solutions, has partnered with Molecular Instruments (MI), the inventor of HCR Imaging technology. This collaboration introduces HCR Pro RNA-ISH technology to Leica’s BOND RX and BOND RXm research staining instruments, enabling enhanced RNA and protein detection capabilities.
How Does HCR Pro RNA-ISH Elevate Cancer Research?
The partnership between Leica Biosystems and Molecular Instruments leverages the HCR Pro RNA-ISH platform, a groundbreaking tool that provides brightfield and fluorescent imaging of RNA targets. Designed for formalin-fixed, paraffin-embedded (FFPE) tissue samples, this technology empowers researchers to extract deeper spatial insights by detecting RNA and protein on the same tissue sample.
By integrating HCR Pro RNA-ISH with Leica’s BOND RX systems, researchers gain access to automated, high-throughput workflows. This advancement conserves precious tissue samples while unlocking new possibilities for studying RNA expression patterns and protein interactions.
Dr. Aneesh Acharya, Chief Commercial Officer at Molecular Instruments, remarked on the significance of the collaboration: “Users have rapidly adopted HCR Pro kits on their instruments already, but we expect to accelerate that pace through close collaboration with the fantastic team at Leica Biosystems to support the seamless transition from legacy technologies to HCR Pro RNA-ISH.”
What Makes HCR Pro RNA-ISH a Breakthrough Tool?
HCR Pro RNA-ISH offers robust performance and versatility, setting a new standard in RNA imaging. Powered by the Hybridization Chain Reaction (HCR) platform, the technology has revolutionized fluorescent multiplexed imaging over the past decade, providing scientists with tools for quantitative, high-resolution imaging in thick tissue and whole-mount samples.
The RNA-ISH technology’s seamless integration with Leica’s BOND RX systems enhances scalability and efficiency. This pairing allows simultaneous RNA and protein analysis while maintaining compatibility with existing immunohistochemistry (IHC) and immunofluorescence (IF) workflows.
Karan Arora, Senior Vice President of Advanced Assays and Pharma Services at Leica Biosystems, emphasized the importance of this innovation: “By combining innovation and automation, we empower researchers with a powerful platform to unlock deeper insights into RNA expression and advance our understanding of cancer biology.”
Why Does This Partnership Matter for Cancer Research?
Cancer research relies on precise and scalable diagnostic tools to analyze complex cellular processes. This collaboration underscores Leica Biosystems’ commitment to driving innovation in cancer diagnostics. Its expertise in biopsy-to-diagnosis solutions, combined with Molecular Instruments’ HCR platform, creates an unparalleled synergy.
Leica Biosystems has long been a leader in providing comprehensive workflow solutions that span radiology, pathology, surgery, and oncology. With this new partnership, the company reinforces its mission to “Advance Cancer Diagnostics, Improve Lives.”
Similarly, Molecular Instruments has built a strong reputation for its protease-free workflow, native compatibility with existing assays, and accessible pricing models. HCR Pro RNA-ISH products are designed for universal adoption, featuring free custom probe designs and introductory starter kits.
What’s Next for RNA-ISH Research?
The introduction of HCR Pro RNA-ISH technology marks a pivotal moment in RNA imaging. With enhanced scalability, precision, and accessibility, researchers worldwide can advance their understanding of complex biological processes at a faster pace.
Leica Biosystems and Molecular Instruments aim to support laboratories transitioning from traditional RNA imaging methods to this next-generation solution. Their combined expertise ensures streamlined adoption and optimized results, setting the stage for further innovations in cancer biology and pathology.
Expert Perspectives on the Partnership
Industry experts view this collaboration as a milestone for the life sciences sector. The integration of HCR Pro RNA-ISH with Leica’s automated staining platforms not only enhances the efficiency of laboratory workflows but also paves the way for groundbreaking discoveries in RNA-protein interactions.
“This collaboration with Molecular Instruments is a pivotal step in making this innovative technology more accessible and scalable for cancer research,” Arora added. “By expanding the capabilities of BOND RX systems, we’re enabling researchers to unlock unprecedented insights into RNA expression.”
Advancing Diagnostics, Improving Lives
The partnership between Leica Biosystems and Molecular Instruments embodies the future of cancer diagnostics. By combining HCR Pro RNA-ISH technology with the scalability and automation of BOND RX systems, the collaboration is set to redefine RNA research and improve outcomes in cancer biology.
As the life sciences community continues to explore the potential of RNA imaging, this innovative solution promises to drive significant advancements in understanding disease mechanisms and developing targeted therapies.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.